12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nenad lisuride transdermal patch regulatory update

EMEA's CHMP issued a negative opinion on an MAA from Axxonis for Nenad lisuride transdermal patch to treat restless legs syndrome (RLS). CHMP said there was not enough evidence...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >